Jazz Pharmaceuticals (JAZZ) Set to Announce Earnings on Wednesday

Jazz Pharmaceuticals (NASDAQ:JAZZ) will be releasing its earnings data after the market closes on Wednesday, May 1st. Analysts expect Jazz Pharmaceuticals to post earnings of $3.55 per share for the quarter. Jazz Pharmaceuticals has set its FY24 guidance at $18.15-$19.35 EPS and its FY 2024 guidance at 18.150-19.350 EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.01 billion. On average, analysts expect Jazz Pharmaceuticals to post $16 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $109.46 on Monday. Jazz Pharmaceuticals has a 1 year low of $106.61 and a 1 year high of $146.70. The company has a current ratio of 2.24, a quick ratio of 1.85 and a debt-to-equity ratio of 1.37. The firm’s 50 day moving average is $118.25 and its 200-day moving average is $121.69. The firm has a market capitalization of $6.90 billion, a price-to-earnings ratio of 17.89, a PEG ratio of 1.51 and a beta of 0.59.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CFO Philip L. Johnson bought 12,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, March 1st. The shares were purchased at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now owns 27,932 shares in the company, valued at approximately $3,342,063.80. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CAO Patricia Carr sold 1,936 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the transaction, the chief accounting officer now owns 8,364 shares in the company, valued at $1,000,668.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Philip L. Johnson acquired 12,000 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were bought at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now owns 27,932 shares of the company’s stock, valued at $3,342,063.80. The disclosure for this purchase can be found here. 4.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on JAZZ shares. Stifel Nicolaus lifted their target price on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Robert W. Baird began coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $160.00 target price on the stock. JPMorgan Chase & Co. lifted their price target on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a research report on Friday, March 22nd. Needham & Company LLC restated a “buy” rating and issued a $220.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. Finally, Truist Financial reaffirmed a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $195.08.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.